Experimental treatment reveals copper nanozymes reduce inflammation and bacterial polysaccharides in burn-induced lung injury, suggesting a dual-target approach.
Acute lung injury (ALI), especially burn-induced cases complicated by secondary infections and hyperinflammation, remains challenging to treat. This study developed 4-mercaptobenzoic acid (MPBA)-modified copper nanozymes (CuMPBA) to simultaneously combat bacterial infections and toxin-triggered immune overactivation. CuMPBA binds bacterial surface polysaccharides via boronate ester bonds, neutralizing lipopolysaccharides (LPS) and lipoteichoic acid (LTA). It demonstrates dual enzymatic activity: peroxidase (POD)-like and glutathione peroxidase (GPx)-like activities for antimicrobial effects. Additionally, CuMPBA disrupts Streptococcus pneumoniae (Sp) metabolism by interfering with thiamine utilization, amino acid synthesis, DNA processes, and energy production. In burn-ALI mice with secondary pneumonia, CuMPBA restored lung architecture, suppress TNF-α/IL-1β/IL-6 levels, and modulated inflammatory pathways by activating Nrf2 while inhibiting NF-κB. These synergistic mechanisms (precise bactericidal action combined with toxin neutralization) establish CuMPBA as a promising dual-target therapeutic strategy for complex burn-associated ALI. The multifunctionality of nanozymes addresses both infection control and inflammation resolution, offering new potential for managing this severe pathological condition.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: